Analyst consensus rating
Krystal Biotech Analyst Rating: Strong Buy
KRYS is rated Strong Buy by 8 analysts with a $385.00 target. As of 2026-08-28.
Direct answer
Krystal Biotech's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $385.00.
Forecast evidence checked August 28, 2026.
Get free Krystal Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $357.46
- Average price target
- $385.00
- High price target
- $474.00
- Low price target
- $284.00
- Low target gap
- -20.6%
- Target upside
- +7.7%
- High target gap
- +32.6%
- Target range width
- 53.2%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Krystal Biotech?
Krystal Biotech has a verified Strong Buy consensus. The same dataset has an average price target of $385.00.
How far are Krystal Biotech's low and high targets from the recorded price?
The low target implies -20.6%, while the high target implies +32.6%.
How many analysts are included in Krystal Biotech's consensus?
The verified consensus includes 8 analysts.
How is Krystal Biotech's target upside or downside calculated?
The average target of $385.00 is divided by the recorded price of $357.46, then one is subtracted to produce +7.7%. This does not guarantee a future return.
When was Krystal Biotech's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.